ID   LAMA84R
AC   CVCL_AE17
SY   LAMA84-R
DR   Wikidata; Q54901919
RX   PubMed=10688835;
CC   Selected for resistance to: ChEBI; CHEBI_45783; Imatinib (Gleevec; STI571).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Lys319Ter (c.955A>T); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0388 ! LAMA-84
SX   Female
AG   29Y
CA   Cancer cell line
DT   Created: 23-02-16; Last updated: 19-12-24; Version: 13
//
RX   PubMed=10688835; DOI=10.1182/blood.V95.5.1758.005a41_1758_1766;
RA   le Coutre P., Tassi E., Varella-Garcia M., Barni R., Mologni L.,
RA   Cabrita G., Marchesi E., Supino R., Gambacorti-Passerini C.;
RT   "Induction of resistance to the Abelson inhibitor STI571 in human
RT   leukemic cells through gene amplification.";
RL   Blood 95:1758-1766(2000).
//